Physician

Mark D Erickstad, M.D.

According to 2025 Medicare claims, Mark Erickstad, M.D. (NPI: 1972570307) practices urology in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 75605-5205. Erickstad is affiliated with the CHSPSC ACO 8, LLC (ACO ID: A3715), participating under the MSSP model.

Erickstad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 846 traditional Medicare patients, billed 11,372 HCPCS/CPT codes, and received $288,980 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,725 prescription claims across 809 beneficiaries totaling $173,196 in drug costs, led by Myrbetriq (Mirabegron). DME data shows 26 claims. Open Payments data shows 10 records totaling $194. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $258,896 and ending at $288,980. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $150 and ending at $226.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	853	21,185	$258,896
2016	873	16,097	$301,640
2017	939	29,122	$296,228
2018	856	34,345	$232,816
2019	892	41,938	$254,276
2020	759	26,602	$225,183
2021	794	34,074	$413,183
2022	804	32,683	$381,239
2023	818	32,757	$294,015
2024	846	11,372	$288,980

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	588	2,796	$233,123
2016	619	2,993	$229,694
2017	662	3,371	$261,475
2018	780	3,638	$271,799
2019	742	3,648	$241,158
2020	655	3,424	$215,519
2021	722	3,424	$199,878
2022	703	3,238	$215,578
2023	759	3,377	$218,414
2024	809	3,725	$173,196

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	72	$37,430
2016	N/R	96	$50,449
2017	N/R	126	$52,419
2018	N/R	101	$44,992
2019	N/R	80	$35,338
2020	N/R	62	$41,132
2021	N/R	54	$28,873
2022	N/R	35	$20,533
2023	N/R	27	$19,905
2024	N/R	26	$24,291

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	556	957	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	209	234	$59
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	198	216	$39
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	570	848	$12
81003	Automated urinalysis test	745	1,334	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Myrbetriq	Mirabegron	70	3,363	$45,960
Elmiron	Pentosan Polysulfate Sodium	15	630	$18,147
Gemtesa	Vibegron	22	1,040	$16,310
Tamsulosin Hcl	Tamsulosin Hcl	889	60,043	$13,201
Doxycycline Monohydrate	Doxycycline Monohydrate	286	19,013	$10,813

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4352	Intermittent urinary catheter; coude (curved) tip, with or without coating (teflon, silicone, silicone elastomeric, or hydrophilic, etc.), each	N	N/R	15	$14,357
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	11	$9,934

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$194	Olympus America Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark D. Erickstad, M.D.?

Tedicare shows public-source Medicare data for Mark D. Erickstad, M.D. (NPI 1972570307), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark D. Erickstad, M.D. have ACO affiliation data?

Mark D. Erickstad, M.D. is shown with ACO affiliation data for CHSPSC ACO 8, LLC (MSSP, ACO ID A3715).

What billing organization is linked to Mark D. Erickstad, M.D.?

Mark D. Erickstad, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Mark D. Erickstad, M.D. have Open Payments data?

Mark D. Erickstad, M.D. has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.